BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31609782)

  • 1. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 12. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
    Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
    Frick M; Bettstetter M; Bertz S; Schwarz-Furlan S; Hartmann A; Richter T; Lenze D; Hummel M; Dreyling M; Lenz G; Gaumann A
    Leuk Lymphoma; 2018 May; 59(5):1260-1263. PubMed ID: 28868954
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
    Xu PP; Shen R; Shi ZY; Cheng S; Wang L; Liu Y; Zhang L; Huang R; Ma X; Wu X; Yao H; Yu Y; Zhao WL
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1051-e1058.e1. PubMed ID: 36182550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.